Summit Therapeutics Inc. Common Stock

SMMT XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

12B

Short interest (May 15)

3.8%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.54%

↑ 4.1%

Available Shares

↑ 31.1%

Price Chart

Company Overview

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001599298

Asset Type: CS

Market Data

Market Cap: $11,533,776,904

Employees: 265

Status: Active

Short Interest

Current Borrow Fee 0.54%

Range: 0.54% - 0.63%

Available Shares 1M

Range: 1M - 1.4M

Recent Changes

Fee Change: ↑ 5.7%

Available Change: ↓ 25.8%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime